This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Institut Pasteur De Lille, Universitá Degli Studi Di Pavia. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2019
Title: Jerome Vicogne: Innovator in Tissue Regeneration
Introduction
Jerome Vicogne is a notable inventor based in Perenchies, France. He has made significant contributions to the field of biotechnology, particularly in the area of tissue regeneration. His work focuses on the development of proteins that can activate the MET receptor, which plays a crucial role in cellular processes.
Latest Patents
Vicogne holds a patent for MET receptor agonist proteins. This patent discloses proteins derived from the HGF/SF that are capable of inducing activation of the tyrosine kinase receptor MET. The patent also covers the uses of these proteins, particularly in promoting tissue regeneration. Additionally, it includes nucleic acid molecules coding for such proteins, expression vectors containing these nucleic acid molecules, host cells with these expression vectors, and related compositions.
Career Highlights
Throughout his career, Jerome Vicogne has worked with prestigious institutions such as the Centre National de la Recherche Scientifique and the Institut Pasteur de Lille. His experience in these organizations has allowed him to advance his research and contribute to significant scientific advancements.
Collaborations
Vicogne has collaborated with notable colleagues, including Oleg Melnyk and Nathalie Ollivier. These partnerships have further enriched his research and innovation in the field.
Conclusion
Jerome Vicogne's work in developing MET receptor agonist proteins showcases his commitment to advancing tissue regeneration technologies. His contributions are vital to the ongoing research in biotechnology and have the potential to impact medical treatments significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile